Dual-Action Mechanism — Why Levodropropizine and Chlorpheniramine Work Together
This combination targets allergic dry cough through two distinct and complementary pharmacological pathways.
Levodropropizine 30mg is a peripherally acting antitussive — a critical distinction from narcotic and central cough suppressants like codeine or dextromethorphan. Rather than acting on the brain's cough centre, levodropropizine works directly at the level of peripheral sensory nerve endings in the bronchial mucosa. It inhibits the release of neuropeptides — particularly substance P — that sensitise airway C-fibres and trigger the cough reflex. This peripheral mechanism produces effective cough suppression without sedation, respiratory depression, or dependence risk, making levodropropizine syrup significantly safer for daily use in adults and children.
Chlorpheniramine Maleate 2mg is a first-generation H1 antihistamine that blocks histamine receptors in the nasal mucosa, upper respiratory tract, and bronchial tissue. In allergic cough, histamine release from mast cells triggers mucosal oedema, increased secretions, and post-nasal drip — all of which act as mechanical cough triggers even after the original allergen exposure has passed. Chlorpheniramine addresses this inflammatory component, reducing the allergic stimulus that repeatedly reactivates the cough reflex.
Together, these two agents deliver both neural cough suppression and anti-allergic mucosal control — a combination specifically suited to allergic cough syrup requirements across India's high-allergen, high-pollution respiratory disease burden.
Levodropropizine and Chlorpheniramine Maleate Syrup Uses — Conditions This Formulation Targets
he levodropropizine and chlorpheniramine maleate syrup uses span allergic and irritant-driven respiratory conditions where the cough reflex is hypersensitised rather than productive.
Dry Cough from Allergic Rhinitis
Cough syrup for allergic rhinitis is one of the highest-volume prescribing categories for this combination. Allergic rhinitis triggers post-nasal drip, nasal congestion, and histamine-mediated airway irritation — all of which sustain dry, non-productive cough that expectorants cannot address. The dual-action formula suppresses both the neural cough trigger and the allergic mucosal response driving it.
Post-Nasal Drip Cough
Post-nasal drip cough syrup formulations need to address the mechanical irritation of secretions dripping onto the posterior pharynx and the inflammatory mucosal response maintaining secretion. Chlorpheniramine reduces histamine-driven hypersecretion while levodropropizine suppresses the resulting peripheral cough sensitisation.
Allergic Bronchitis
Allergic bronchitis cough syrup requirements call for an agent that can calm an irritated bronchial tree without sedating the patient. Levodropropizine's peripheral action directly reduces bronchial sensory nerve excitability, providing relief in allergic bronchitis without the CNS burden of centrally acting antitussives.
Dry Cough After Upper Respiratory Tract Infections (URTI)
Post-viral dry cough — where airway nerve hypersensitivity persists weeks after the original infection has resolved — is a major driver of dry cough medicine for adults India prescriptions. The peripheral desensitisation mechanism of levodropropizine is particularly effective in this post-infectious hypersensitivity state.
Night-Time Allergic Cough
Cough syrup for night cough allergy India represents a significant prescription segment. Allergic and irritant cough frequently worsens at night due to increased post-nasal drip in the supine position and circadian changes in airway tone. The chlorpheniramine component's mild sedative effect at the prescribed 2mg dose can be advantageous at night — reducing histamine-driven nocturnal cough while allowing restful sleep.
Dust Allergy and Chronic Dry Cough
Chronic dry cough triggered by dust, pollution, or occupational allergen exposure — a common presentation across Indian cities — responds to this combination's dual suppression of both the neural cough arc and the histamine-mediated mucosal trigger.
Third Party & Contract Manufacturing — Levodropropizine Chlorpheniramine Syrup
Delwis Healthcare is a WHO-GMP certified third party pharmaceutical manufacturer and CDMO partner for levodropropizine and chlorpheniramine maleate syrup — serving respiratory brands, anti-allergic medicine companies, and pharmaceutical exporters building their cough and allergy product range.
Third Party Manufacturing — Full GMP-compliant production of levodropropizine 30mg chlorpheniramine 2mg per 5ml syrup in 100ml packs under your brand name — with formulation, filling, labeling, and carton included.
Contract Manufacturing (CDMO) — End-to-end partnership covering API sourcing, formulation development, process validation, stability studies, and commercial batch supply with complete regulatory documentation.
Private Label Manufacturing — Custom brand name, label design, carton artwork, and flavoring profile tailored to your target market and therapeutic positioning.
Bulk Supply — Commercial-scale consistent batch production for institutional buyers, hospital formularies, government tenders, and export distribution with full batch COA and documentation.
Oral Liquid Manufacturing Facility — Syrup Production Capability at Delwis Healthcare
Delwis Healthcare's WHO-GMP, ISO 9001, and ISO 14001 certified facility in Ahmedabad is equipped for the manufacture of levodropropizine chlorpheniramine maleate syrup and other oral liquid pharmaceutical formulations:
- High-shear mixing and homogenisation systems for uniform API dispersion across the 100ml batch
- Controlled-temperature processing to maintain API and excipient stability throughout blending
- Inline pH and viscosity monitoring ensuring consistent batch-to-batch product characteristics
- Automated volumetric liquid filling lines with seal integrity verification for 100ml bottles
- Dedicated oral liquid production suites preventing cross-contamination between therapeutic categories
- Full batch traceability through electronic batch records and QMS documentation aligned with WHO-GMP requirements
Quality Control — GMP Certified Cough Syrup Manufacturer Ahmedabad
Every batch of levodropropizine and chlorpheniramine maleate syrup manufactured at Delwis Healthcare is released only after clearing a validated QC programme:
- HPLC Assay — Separate quantification of levodropropizine and chlorpheniramine maleate against certified reference standards
- pH Determination — Confirmed within validated specification critical for both formulation stability and palatability
- Viscosity Measurement — Ensures consistent pourability and accurate dose delivery from the 5ml measuring spoon
- Clarity and Colour Check — Visual and instrumental inspection for particle-free, colour-consistent batches
- Microbial Limit Testing — Microbiological safety compliance for oral liquid formulations per IP/BP requirements
- Preservative Efficacy Testing — Antimicrobial effectiveness confirmed across the validated shelf life
- Stability Studies — Real-time and accelerated stability data on file for regulatory dossier submissions
Choosing Delwis Healthcare as Your Cough Syrup Manufacturing Partner
Pharmaceutical brands and respiratory medicine companies partner with Delwis Healthcare for levodropropizine chlorpheniramine syrup third party manufacturing because:
- WHO-GMP & ISO 9001/14001 Certified — Accepted for CDSCO domestic and export market regulatory submissions
- Dedicated Oral Liquid Manufacturing Suites — Purpose-built syrup production lines with controlled-environment processing
- Peripheral Antitussive Formulation Expertise — Specialist experience in non-narcotic antitussive and anti-allergic syrup manufacturing
- Accurate Dual-API Dosing — Validated blending and filling systems ensuring correct levodropropizine and CPM concentrations per 5ml dose
- Flexible MOQ — Scalable from pilot batches to large commercial volumes
- Full CDMO Capability — Formulation development, stability studies, and regulatory documentation support
- Export-Ready Documentation — COA, stability data, and manufacturing licence available for international market submissions
- Competitive Manufacturing Cost — Cost-efficient oral liquid production from Ahmedabad, Gujarat
Questions About Levodropropizine and Chlorpheniramine Maleate Syrup
Q1: What is levodropropizine and chlorpheniramine maleate syrup used for?
Levodropropizine and chlorpheniramine maleate syrup uses include dry cough caused by allergic rhinitis, post-nasal drip, allergic bronchitis, dust and pollen allergy, cough following upper respiratory tract infections, and night-time allergic cough. The combination is specifically indicated for non-productive dry cough where both neural cough suppression and anti-allergic mucosal control are required.
Q2: How does levodropropizine syrup work for dry cough?
Levodropropizine is a peripherally acting antitussive that works at bronchial sensory nerve endings — inhibiting neuropeptide release that sensitises airway C-fibres and triggers the cough reflex. Unlike narcotic antitussives which act on the brain's cough centre, levodropropizine suppresses cough at the peripheral airway level without CNS sedation or dependence risk.
Q3: Is levodropropizine a narcotic cough suppressant?
No. This is an important clinical distinction. Levodropropizine is not a narcotic — it is a non-narcotic, peripherally acting antitussive with no opioid activity, no CNS depression, and no dependence potential. This makes it significantly safer than codeine-based cough syrups, particularly for use in children and for patients requiring repeated or extended cough suppression therapy.
Q4: What is the difference between levodropropizine and dextromethorphan?
Both are non-narcotic antitussives, but they act at different sites. Dextromethorphan is a centrally acting antitussive that suppresses the cough reflex in the medulla — producing mild CNS effects including sedation and, at high doses, dizziness. Levodropropizine acts peripherally at bronchial sensory nerves, producing equivalent cough suppression without central nervous system involvement — making it the preferred option where CNS side effects are a concern, including in children, elderly patients, and those operating vehicles or machinery.
Q5: Can levodropropizine chlorpheniramine syrup cause drowsiness?
Levodropropizine itself does not cause drowsiness due to its peripheral mechanism. Chlorpheniramine maleate at the 2mg/5ml dose carries mild antihistamine sedation — which may be perceived as a disadvantage during the day but is clinically useful for night-time allergic cough where some sedation aids restful sleep. Patients should be counselled about this when taking daytime doses.
Q6: What is the dosage of levodropropizine and chlorpheniramine syrup?
Standard adult dosage is 10ml (two 5ml doses) three times daily. Paediatric dosing is weight-based and typically 5ml two to three times daily for children above 2 years, under physician guidance. Dosage should always be prescribed by the treating physician based on age, weight, and clinical indication.
Q7: Should levodropropizine syrup be taken before or after food?
Levodropropizine chlorpheniramine syrup can be taken with or without food. However, taking it after food is generally recommended for patients who experience mild gastric discomfort, and it may reduce the sedative effect of chlorpheniramine when taken on a full stomach. Follow the prescribing physician's specific instructions.
Q8: Is levodropropizine syrup safe for children?
Levodropropizine syrup is used in children above 2 years under medical supervision with weight-appropriate dosing. Its peripheral mechanism makes it preferable to central antitussives in the paediatric age group. Use in children below 2 years should only be under direct specialist guidance. Always use as prescribed by the treating paediatrician.
Q9: Do you offer third party manufacturing for levodropropizine chlorpheniramine syrup?
Yes. Delwis Healthcare is a WHO-GMP certified antitussive syrup manufacturer in Ahmedabad offering complete third party and contract manufacturing of levodropropizine 30mg + chlorpheniramine maleate 2mg per 5ml syrup in 100ml packs — under your brand name, with custom labeling, carton packaging, and full regulatory documentation. Contact info@delwishealthcare.com for manufacturing enquiries.
